Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or o ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Edward Dulac - Chief Financial Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Matt Biegler - Oppenheimer Kelsey Goodwin - Guggenheim Securities Ben Burnett - Stifel Biren Amin - Jefferies Daina Graybosch - SVB ...

I think UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdict ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q2 2020 Earnings Conference Call August 5, 2020 5:30 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Robyn Karnauskas - Truist Securities Kelsey Goodwin - Guggenheim Securities Daina Graybosch - SVB Leerink Mara Goldstein - Mizuho Peter Lawson - Barclays Matt Biegler - Oppenh ...

I think UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERA ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Ted Tenthoff - Piper Sandler Robyn Karnauskas - SunTrust Robinson Jim Birchenough - Wells Fargo Alethia Young - Cantor Daina Graybosch - SVB Leerink David Nierengarten - Wedbush Securities Biren Amin - Jefferies Mara Goldstein - Mizuho Ben Burnett - Stifel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 (Exact name of re ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2019 Earnings Conference Call March 2, 2020 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Daniel Shoemaker - Chief Scientific Officer Wayne Chu - Senior Vice President of Clinical Development Conference Call Participants Mara Goldstein - Mizuho Securities USA LLC Alethia Young - Cantor Fitzgerald & Co. James Birchenough - Wells Fargo Securities, LLC Edward Tenthoff - Piper Sandler & Co. Benjamin Burnett - Stifel, Nicolaus & Com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | |-------| | | | | | | | ...

Better Cells For Better Therapies™ | --- | --- | |-----------------------------------------------------------------------|-------| | | | | Off-the-shelf Cell-based Cancer Immunotherapy | | | Developing First-of-kind Cell Products using Clonal Master iPSC Lines | | | 2019 ASH Dinner Discussion | | | December 6, 2019 | | - Jeffrey S. Miller, MD Cells For Better Therapies TM Deputy Director, Masonic Cancer Center Director, Cancer Experimental Therapeutics Join Us for Dinner Initiative (CETI), University of Min ...